Revista internacional de innovaciones, pensamientos e ideas avanzadas

Abstracto

Potential of KLS-13019 to Serve as Non-Addicting and Non-Opioid Option for Neuropathic and Chronic Pain Relief

Dean Petkanas

According to the White House drug policy office, drug-related fatalities increased by 11.4% year-over-year in the first four months of 2020. As opioid overdose deaths skyrocket across the U.S. during the COVID-19 pandemic, emphasis needs to be placed on proactively creating non-opioid solutions for pain relief. Kannalife, Inc., a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, has been working on a non-opioid solution for pain through its laboratory-created cannabidiol (CBD)-like molecule KLS-13019. In research funded by a grant from the National Institutes of Health’s National Institute on Drug Abuse